Brugada Syndrome: The Genetic Heart Condition Behind Some Unexplained Sudden Deaths
Imagine a healthy young person playing sports, feeling fine, and suddenly collapsing without warning. Their heart stops beating properly, and they lose consciousness. Without immediate emergency care, they could die within minutes. What makes this tragedy especially heartbreaking is that many of these victims had no previous symptoms—they seemed perfectly healthy. In some cases, autopsies reveal no obvious cause of death, leaving families devastated and confused. However, scientists have discovered that many of these unexplained sudden deaths result from a genetic heart condition called Brugada syndrome. Brugada syndrome is a rare inherited disorder affecting how the heart’s electrical system functions. Unlike other heart diseases that damage the heart muscle itself, Brugada syndrome creates dangerous electrical disturbances that can trigger fatal heart rhythms called ventricular fibrillation. This condition kills approximately 4 to 10 people per million worldwide annually, making it a significant cause of sudden unexpected death in young people, particularly in males. What makes Brugada syndrome particularly dangerous is that many people with the condition have no symptoms and no knowledge they carry this genetic risk. They may seem completely healthy until a fatal arrhythmia occurs, often during sleep or rest. However, modern medical science has developed methods to identify people with Brugada syndrome before tragedy strikes and treatments that can save their lives. In this comprehensive article, we will explore what Brugada syndrome is, how genetic mutations cause it, what triggers dangerous heart rhythms, how doctors diagnose it, available lifesaving treatments, and how people can manage this hidden threat to their lives.
Understanding Your Heart’s Electrical System
To understand Brugada syndrome, we first need to understand how the normal heart works and what role the heart’s electrical system plays. Your heart is a muscular pump consisting of four chambers—two upper chambers called atria and two lower chambers called ventricles. These chambers must contract in a precise, coordinated sequence to pump blood efficiently throughout your body. The heart’s electrical system controls this coordinated beating. Specialized cells called pacemaker cells generate electrical impulses that spread through the heart muscle, triggering coordinated contractions. The main pacemaker is the sinoatrial node, located in the right atrium. This node generates electrical impulses approximately 60 to 100 times per minute in healthy adults, setting your normal heart rate. Electrical impulses travel along specific pathways through the heart muscle, spreading in an organized sequence. This electrical propagation ensures that the atria contract first, pumping blood into the ventricles, followed by the ventricles contracting to pump blood out of the heart. The electrocardiogram (ECG) is a simple test that records the heart’s electrical activity, showing the impulses and their spread through the heart. On a normal ECG, specific waves represent different parts of the electrical cycle—the P wave shows atrial activity, the QRS complex shows ventricular activity, and the T wave shows the heart muscle’s recovery phase. The electrical system’s precise timing is controlled by channels in the heart muscle cells that allow ions like sodium, calcium, and potassium to flow in and out. These ion channels are proteins embedded in cell membranes, acting like specialized gates regulating ion movement. When ions flow through these channels at the right times, proper electrical function occurs. When ion channel function is abnormal, dangerous rhythm disturbances can develop. Brugada syndrome results from mutations in genes encoding these ion channel proteins, primarily the SCN5A gene that codes for sodium channels. These mutations create abnormal ion channels that malfunction, disrupting the heart’s electrical system and creating conditions for dangerous arrhythmias.
What is Brugada Syndrome and How Does It Develop?
Brugada syndrome is an inherited cardiac arrhythmia disorder caused by genetic mutations affecting the heart’s ion channels, specifically sodium channels. The disease is autosomal dominant, meaning you need only inherit one copy of the mutated gene from one parent to develop the condition. If one parent has Brugada syndrome, each child has a 50 percent chance of inheriting the mutation and developing the syndrome. The SCN5A gene is the most commonly mutated gene in Brugada syndrome, accounting for about 20 to 30 percent of cases. This gene encodes the alpha subunit of the cardiac sodium channel, crucial for rapid sodium ion entry during the heart’s electrical activity. Mutations in this gene produce sodium channels that do not function properly, reducing the sodium current in the heart. Other genes involved in Brugada syndrome include CACNA1C, CACNB2b, GPD1L, and others, though these account for smaller percentages of cases. The ion channel dysfunction in Brugada syndrome creates an electrical imbalance in the right ventricle. The right ventricle becomes more excitable than the left ventricle due to reduced sodium current. This imbalance creates areas of the heart that depolarize at different rates, creating the conditions for re-entrant arrhythmias. Re-entrant arrhythmias occur when electrical impulses circulate through the heart tissue repeatedly, creating chaotic, rapid, and disorganized beating. This disorganization prevents effective pumping, and blood pressure falls dangerously. If the ventricles are fibrillating, no blood flows to the brain, and loss of consciousness occurs within seconds. Without immediate treatment, ventricular fibrillation causes death within minutes. The dangerous arrhythmias in Brugada syndrome often occur during sleep or at rest, particularly at night. This is because body temperature, vagal tone, and hormonal factors during sleep increase the risk of arrhythmias in susceptible individuals. Some people experience symptoms only occasionally, while others are at high risk. Interestingly, some people carrying Brugada mutations never experience dangerous arrhythmias during their lifetime, though they carry the genetic risk.
The Characteristic ECG Pattern: Brugada Type 1
One of the most distinctive features of Brugada syndrome is a specific pattern visible on an electrocardiogram called the Brugada Type 1 pattern. This pattern was first described in 1992 by Spanish brothers Josep and Pedro Brugada, who recognized this ECG pattern in patients experiencing sudden nocturnal unexplained nocturnal death syndrome (SUNDS), a phenomenon documented in Southeast Asia for centuries. The Brugada Type 1 pattern shows characteristic changes in the QRS complex and ST segment. The most distinctive feature is a coved ST segment elevation in leads V1 and V2—the leads recording electrical activity in the right ventricle. The ST segment rises abruptly like a roof’s peak, then drops suddenly, creating a distinctive tent-shaped or coved appearance. This coved ST elevation is followed by a negative T wave. The term “Type 1” Brugada pattern refers to this characteristic coved ST elevation. There are also Type 2 and Type 3 patterns showing saddle-back ST elevation or minor ST elevation, which are more borderline findings. Type 1 pattern is the most diagnostic and specific for Brugada syndrome. However, not all people carrying Brugada mutations show this pattern consistently—the ECG can appear normal sometimes and abnormal other times. This is called “dynamic” ECG changes, where the Brugada pattern appears and disappears. Several factors can make the Brugada pattern more or less apparent on ECG. High fever increases the likelihood of showing the Type 1 pattern. Certain medications, particularly sodium channel blockers like flecainide, can unmask or accentuate the pattern. This is sometimes used diagnostically—giving flecainide to patients with suspected Brugada syndrome and then checking the ECG can unmask hidden patterns. Alcohol use and sleep deprivation can increase arrhythmia risk. Body temperature changes affect the pattern visibility. Low body temperature during hypothermia can unmask the pattern. Vagal maneuvers that increase parasympathetic nervous system activity can make the pattern more apparent. Eating large meals can unmask the pattern in some cases. Fatigue and excessive exertion sometimes trigger pattern appearance. This dynamic nature of the ECG pattern complicates diagnosis and explains why some people are found to have Brugada syndrome only incidentally or after experiencing symptoms.
Who Gets Brugada Syndrome and Why Some Are at Higher Risk
Brugada syndrome affects approximately 1 to 5 people per million worldwide, making it rare but not extremely uncommon. However, prevalence varies significantly by geography and ethnicity. Southeast Asian countries have much higher prevalence, particularly Thailand, Philippines, and Vietnam. In these countries, the disease was historically known as SUNDS (Sudden Unexplained Nocturnal Death Syndrome) because it killed people, particularly men, during sleep. Prevalence in Southeast Asia may be 20 to 50 times higher than in Western countries. The genetic pool in Southeast Asian populations carries more Brugada mutations, suggesting evolutionary or historical factors increasing prevalence. Brugada syndrome shows distinct male predominance, affecting men 8 to 10 times more frequently than women. The reason for this sex difference is not completely understood but appears related to sex hormones. Testosterone may increase arrhythmia risk in men. Estrogen may be protective in women. This is supported by observations that women’s symptoms sometimes worsen after menopause. Young and middle-aged adults are most commonly affected, with average age of first symptoms around 40 years. However, children and elderly people can develop symptoms. Genetic factors are the primary determinant of Brugada syndrome development. Inheriting a Brugada mutation significantly increases arrhythmia risk. However, not everyone inheriting a mutation develops symptoms—penetrance is incomplete and variable. Environmental triggers significantly modulate symptom expression. Fever is a powerful trigger, and even mild infections can precipitate dangerous arrhythmias. Sleep, particularly REM sleep, increases risk. Alcohol use, particularly heavy drinking, can trigger arrhythmias. Certain medications block sodium channels and increase arrhythmia risk. Cocaine and other drugs can trigger arrhythmias. Fatigue and exhaustion increase risk. Emotional stress can trigger arrhythmias in some people. Vagal stimulation increases risk in some patients. These modulating factors explain why some mutation carriers remain asymptomatic while others experience life-threatening arrhythmias.
Recognizing Warning Signs and Symptoms
The dangerous aspect of Brugada syndrome is that many people have no symptoms and no warning before a life-threatening arrhythmia occurs. However, some people do experience warning symptoms that prompt diagnosis before tragedy strikes. Syncope, or loss of consciousness, is the most common symptom in symptomatic individuals. Patients suddenly lose consciousness without warning. Syncope often occurs during sleep, explaining why many victims are found dead in bed. Some patients experience syncope during rest or calm activities. Palpitations—the sensation of feeling your heart racing, pounding, or skipping—may precede loss of consciousness. The rapid or irregular heartbeat may feel terrifying. Some patients describe feeling butterflies in their chest or fluttering sensations. These palpitations may last seconds to minutes. Dizziness or lightheadedness sometimes occur before syncope. Patients may feel faint or unsteady. Shortness of breath may accompany palpitations. Some patients report feeling a sudden, intense sense of anxiety or impending doom. Seizures sometimes occur during arrhythmias because reduced blood flow to the brain causes seizure activity. Families may mistakenly believe the person has epilepsy. However, seizures associated with Brugada syndrome occur due to abnormal heart rhythm, not brain electrical abnormalities. Sudden cardiac death can be the first and only symptom. The person appears healthy, then suddenly collapses. Without immediate CPR and defibrillation, death occurs. Many Brugada victims never experienced any symptoms before their fatal arrhythmia. Family history is important—if relatives died suddenly and unexpectedly, Brugada syndrome should be considered. Multiple family members dying suddenly suggests inherited Brugada syndrome. Sudden infant death syndrome (SIDS) is occasionally related to Brugada syndrome mutations. Some cases of SIDS may actually result from Brugada syndrome. Testing siblings and other relatives of SIDS victims can identify Brugada carriers. Many people with Brugada syndrome remain completely asymptomatic throughout life, their genetic condition never causing harm. This unpredictability makes screening important for people with family history or high-risk characteristics.
How Doctors Diagnose Brugada Syndrome
Diagnosing Brugada syndrome requires a combination of clinical suspicion, ECG findings, and sometimes genetic testing. Doctors should suspect Brugada syndrome in several situations: young patients with syncope without obvious cause, family history of sudden cardiac death, patients resuscitated from ventricular fibrillation without obvious heart disease, or people with the characteristic ECG pattern. Electrocardiogram (ECG) is the first diagnostic test. The ECG may show the characteristic Type 1 Brugada pattern with coved ST elevation in leads V1 and V2. However, the pattern may not always be present. High fever is known to unmask the pattern, so some patients intentionally undergo fever testing—they are given medications to trigger mild fever while ECG is monitored. This is called a “fever challenge” test. Flecainide challenge is another diagnostic test. Flecainide is a sodium channel blocker medication given intravenously or orally while ECG is continuously monitored. In people with Brugada syndrome, flecainide accentuates the Type 1 pattern, revealing it if it was not visible before. The flecainide challenge is particularly useful in patients with suspected Brugada syndrome but normal baseline ECG. Genetic testing identifies specific mutations in genes like SCN5A causing Brugada syndrome. Genetic testing provides definitive diagnosis. It also allows identification of specific mutations so family members can be tested for the same mutation. DNA testing identifies whether someone carries a Brugada mutation. Electrophysiology study is sometimes performed to assess arrhythmia risk. During this procedure, catheters are inserted into blood vessels and threaded to the heart. Electrical stimulation is applied to try to trigger dangerous arrhythmias. If dangerous rhythms can be easily triggered, the patient is at higher risk and may benefit from an implantable defibrillator. Holter monitoring or event monitoring records heart rhythm over 24 to 48 hours, detecting arrhythmias if they occur. Echocardiography evaluates heart structure to ensure no other cardiac abnormalities exist. Heart imaging rules out structural heart disease that could cause similar symptoms. Blood tests screen for other conditions that might cause arrhythmias. Exercise stress testing evaluates heart rhythm response to exercise. Interestingly, dangerous arrhythmias in Brugada syndrome typically occur during rest or sleep, not exercise, so exercise test results are usually normal. Family screening is important—relatives of diagnosed patients should undergo ECG and genetic testing.
Treatment: Preventing Sudden Death
Several treatment options exist for Brugada syndrome, ranging from simple measures to advanced cardiac technology. The goal is preventing sudden cardiac death in high-risk individuals. Implantable cardioverter-defibrillator (ICD) is the most effective treatment for people at high risk of sudden death. An ICD is a small battery-powered device implanted under the skin near the collarbone. Wires connect the device to the heart. The ICD continuously monitors heart rhythm. If a dangerous arrhythmia is detected, the device delivers an electric shock to the heart, converting the dangerous rhythm back to normal. ICDs are highly effective, with survival rates exceeding 95 percent in patients with previous syncope or cardiac arrest. The decision to implant an ICD depends on several factors: previous syncope or cardiac arrest is a clear indication for ICD. Asymptomatic patients with high-risk features may also benefit from ICD. High-risk features include male sex, young age, family history of sudden death, presence of Type 1 Brugada pattern, and inducible ventricular fibrillation during electrophysiology study. Asymptomatic patients with no high-risk features may not need an ICD but require close monitoring. Quinidine is an antiarrhythmic medication that blocks potassium channels and can suppress Brugada-related arrhythmias. Quinidine is particularly effective in patients who have experienced syncope. Some studies show quinidine reduces arrhythmia recurrence by 80 to 90 percent. Side effects and drug interactions limit quinidine use in some patients. Isoproterenol is a medication that stimulates beta-adrenergic receptors and increases sympathetic tone. This can suppress arrhythmias in some Brugada patients. Hydroquinidine and other newer antiarrhythmic drugs show promise. Disopyramide is another antiarrhythmic being studied. Avoiding triggers is important for all Brugada patients. Avoiding high fevers—treating fevers promptly with antipyretic medications when ill—reduces risk. Avoiding alcohol, particularly heavy drinking, reduces risk. Avoiding medications known to increase risk—particularly sodium channel blockers. Adequate sleep reduces risk. Managing stress and avoiding excessive fatigue help. Avoiding stimulant drugs reduces risk. Exercise restriction is controversial—some experts recommend avoiding strenuous exercise, while others note that exercise-triggered arrhythmias are rare in Brugada syndrome. Medications should be carefully screened before use to ensure they do not increase arrhythmia risk. Some common medications increase Brugada risk and should be avoided. Regular medical follow-up allows monitoring for new symptoms or ECG changes. Genetic counseling helps families understand inheritance patterns and screening needs.
Living with Brugada Syndrome: Daily Life and Management
People diagnosed with Brugada syndrome face significant psychological and practical challenges adjusting to life with a genetic condition potentially causing sudden death. Many people are asymptomatic and feel completely healthy, making it difficult to accept the diagnosis as serious. However, understanding the condition and following medical recommendations can prevent tragedy. Taking prescribed medications exactly as directed is essential for those receiving antiarrhythmic treatment. Missing doses reduces the protective effect. Regular blood tests monitor medication levels and side effects. Attending all scheduled cardiology appointments ensures proper monitoring. Regular ECGs track for any pattern changes. Periodic electrophysiology testing assesses arrhythmia risk if indicated. Following ICD device checks and maintenance schedules is critical. ICDs require regular device checks to ensure they are functioning properly. Battery status is checked, and software is updated. Device data is reviewed for any detected arrhythmias. Avoiding identified personal triggers reduces arrhythmia risk. Each person’s triggers may be different. Keeping detailed records of activities or circumstances surrounding palpitations helps identify individual triggers. Genetic counseling helps families understand inheritance and screening implications. Family members should undergo testing to identify other carriers. Parents, siblings, and children of affected individuals should be screened. Knowing family members’ status allows them to seek preventive treatment if needed. Psychological support helps people adjust to diagnosis and live fully despite the condition. Counseling addresses anxiety about sudden death. Support groups connect people with others managing Brugada syndrome. Mental health professionals specializing in cardiac disease can provide targeted support. Life planning becomes important for people with Brugada syndrome. Discussing the condition with family and close friends provides understanding and support. Creating a will and advance directives ensures wishes are honored. Discussing genetic implications with partners or potential partners is important. For parents, discussing the condition with children, age-appropriately, helps them understand family health. Employment considerations include ensuring employers understand medical needs and limitations. Some jobs might be inappropriate for people with significant arrhythmia risk. Career planning may need adjustment based on medical needs. Educational planning for young people with Brugada syndrome should consider future needs. Athletic participation is generally acceptable, though specific sports might be restricted based on individual circumstances. Contact sports might be inappropriate for ICD recipients due to device damage risk. Strenuous sports without other restrictions are generally safe. Emotional support from family and friends is essential. Many people feel isolated by their diagnosis. Sharing the burden with trusted people provides support. Online communities provide 24/7 access to others with Brugada syndrome. Some patients find benefit in talking with others who have experienced syncope or cardiac arrest. Social engagement and maintaining normal activities provide normalcy and purpose. Avoiding excessive worry while remaining appropriately cautious is the balance most people seek. Travel is possible with proper planning. People with ICDs should know their device and carry device identification cards. Airport security screening requires special handling of ICD devices. Notifying airlines about ICD status allows proper procedures. Travel insurance should cover cardiac conditions. Accessing medical care while traveling requires planning. Maintaining medications while traveling requires careful packing and planning.
The Genetic Aspect: Family Screening and Counseling
Brugada syndrome is inherited in an autosomal dominant pattern, meaning inheritance is straightforward but implications are significant for families. If one parent has Brugada syndrome, each child has a 50 percent chance of inheriting the mutation. If both parents carry mutations, the risk increases accordingly. Genetic counseling helps families understand these inheritance patterns and implications. Genetic counselors explain how the condition is inherited, what symptoms might occur, and what testing and monitoring are appropriate. Family screening is recommended for all relatives of affected individuals. Parents, siblings, and children should undergo ECG testing. If family members show the Type 1 Brugada pattern or have symptoms, genetic testing can confirm the diagnosis. Negative genetic testing is reassuring but does not guarantee the person will never develop the condition—new mutations can spontaneously arise. Genetic testing specifically identifies the mutation present in the family. Once a family mutation is identified, other relatives can be tested specifically for that mutation. This targeted testing is more accurate and efficient than general screening. Knowing the specific mutation allows better risk stratification—some mutations carry higher risk than others. Prenatal genetic testing is available for couples where one or both parents carry Brugada mutations. This controversial option allows informed reproductive decisions. Some families choose to know this information for prenatal planning. Others prefer to test after birth. Preimplantation genetic diagnosis is another option allowing selection of unaffected embryos in IVF. This technology is not widely available and raises ethical considerations. Psychological support for families receiving a diagnosis of inherited cardiac disease is important. Learning that multiple family members carry a genetic risk creates anxiety. Some family members may feel guilt about potentially passing the condition to children. Others may feel relieved to finally have a diagnosis explaining unexplained deaths in the family. Genetic counseling provides emotional support alongside medical information. Support groups specifically for families with Brugada syndrome provide understanding and practical advice. Children in families with Brugada syndrome need age-appropriate education about the condition. Young children need simple explanations. Adolescents need information supporting independent understanding. Young adults need information for reproductive decision-making. Talking openly about the condition reduces fear and secrecy. Family meetings discussing the condition and its implications help everyone understand. Younger family members benefit from knowing what symptoms to watch for. Knowing family history helps identify carriers before symptoms develop. Information sharing among family members facilitates coordinated testing and care.
Frequently Asked Questions (FAQs)
Q1: Can someone with Brugada syndrome safely exercise?
Yes, most people with Brugada syndrome can exercise safely. Interestingly, dangerous arrhythmias in Brugada syndrome typically occur during rest or sleep, not during exercise. This is opposite to many other cardiac arrhythmia conditions. Most cardiologists encourage normal physical activity and exercise in Brugada patients. However, some high-risk individuals might benefit from exercise restriction. Those with previous syncope or cardiac arrest should discuss exercise with their cardiologist. Competitive sports are generally acceptable. Contact sports might be inappropriate for ICD recipients due to device damage risk. Athletes with Brugada syndrome should work with their doctors to determine appropriate activity levels. Avoiding excessive fatigue and ensuring adequate rest is more important than avoiding exercise.
Q2: Is Brugada syndrome fatal?
Brugada syndrome can be fatal if a dangerous arrhythmia occurs without prompt treatment, but it is not necessarily fatal. Many people with Brugada syndrome remain asymptomatic their entire lives and never experience a dangerous rhythm. With proper identification and treatment, survival is excellent. ICDs prevent sudden death in high-risk individuals with success rates exceeding 95 percent. Antiarrhythmic medications effectively suppress arrhythmias in many patients. The key is identifying people at risk before a fatal arrhythmia occurs and providing appropriate treatment. Regular medical follow-up and family screening can save lives. Undiagnosed Brugada syndrome can be fatal, which is why awareness and screening of at-risk families is so important.
Q3: What makes a fever dangerous in Brugada syndrome?
Fever increases the risk of arrhythmias in Brugada syndrome patients through unknown mechanisms. Even mild fever from minor infections can unmask the Brugada pattern on ECG or trigger dangerous arrhythmias. Some patients have experienced fatal arrhythmias during relatively minor febrile illnesses. This is why fever management is so important in Brugada patients. Prompt antipyretic treatment—taking fever-reducing medications—helps keep body temperature normal. Treating the infection causing fever is important. Some patients carry emergency medications to use if fever develops. Others contact their cardiologist immediately when fever develops for guidance. In high-risk patients, hospitalization during febrile illness for cardiac monitoring might be appropriate. This makes infection prevention through vaccinations particularly important in Brugada patients.
Q4: Can women with Brugada syndrome have normal pregnancies?
Yes, most women with Brugada syndrome can have normal pregnancies, though pregnancy requires careful medical management. During pregnancy, hormonal changes may affect arrhythmia risk. Some women’s symptoms worsen during pregnancy, while others improve. Antiarrhythmic medications may need dose adjustments during pregnancy. Some medications used to treat Brugada syndrome are safe in pregnancy, while others require caution. Discussing pregnancy plans with cardiologists before conception allows appropriate planning. Continuous cardiac monitoring during labor and delivery ensures safety. Women with previous syncope or cardiac arrest should discuss the risks and benefits of pregnancy carefully with their doctors. With proper medical management, many women with Brugada syndrome successfully deliver healthy babies. Genetic counseling helps couples understand that children have a 50 percent risk of inheriting the mutation.
Q5: Why is Brugada syndrome more common in Southeast Asia?
Brugada syndrome prevalence is 20 to 50 times higher in Southeast Asian countries, particularly Thailand, Philippines, and Vietnam, compared to Western countries. This dramatic difference suggests genetic factors—the Southeast Asian population likely has higher frequency of Brugada mutations in the gene pool. Historical SIDS-like deaths in Southeast Asia were sometimes related to Brugada syndrome, suggesting the mutation has been present in these populations for generations. Some evolutionary or founder effect may have increased mutation frequency in Southeast Asian populations. Environmental factors might also play a role—lifestyle factors, dietary factors, or other environmental influences might increase arrhythmia risk in susceptible individuals. The high prevalence in Southeast Asia highlights the importance of genetic screening in these populations and awareness among healthcare providers. Understanding why prevalence differs between populations helps researchers understand the condition better and develop more targeted prevention strategies.
Key Takeaways
Brugada syndrome is a rare genetic heart condition causing dangerous arrhythmias that can lead to sudden cardiac death. The condition results from mutations in genes encoding ion channels, primarily the SCN5A gene. A characteristic ECG pattern shows coved ST elevation in the right precordial leads. Many people with Brugada syndrome are asymptomatic but at risk of sudden death, making diagnosis important for family screening. Diagnosis involves ECG findings, sometimes provocation testing with flecainide, and genetic testing. Implantable defibrillators effectively prevent sudden death in high-risk individuals. Antiarrhythmic medications like quinidine suppress arrhythmias in some patients. Avoiding fever, alcohol, and medications that block sodium channels reduces arrhythmia risk. Family screening allows identification of other carriers before tragedy strikes. With proper diagnosis and treatment, people with Brugada syndrome can live full, normal lives with near-normal life expectancy. Awareness and screening are crucial for saving lives in families with this hidden genetic threat.
References
- World Health Organization (WHO). “Inherited Cardiac Arrhythmias and Sudden Death.” Retrieved from https://www.who.int/
- American Heart Association. “Brugada Syndrome: Information and Resources.” Retrieved from https://www.heart.org/
- Mayo Clinic. “Brugada Syndrome: Causes, Symptoms, and Treatment.” Retrieved from https://www.mayoclinic.org/
- Cleveland Clinic. “Brugada Syndrome: Genetic Heart Condition.” Retrieved from https://my.clevelandclinic.org/
- Brugada Foundation. “Brugada Syndrome: Patient Education and Support.” Retrieved from https://www.brugada.org/
- American College of Cardiology. “Clinical Guidelines for Brugada Syndrome.” Retrieved from https://www.acc.org/
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
